ZA201409006B - Diabetes biomarkers - Google Patents
Diabetes biomarkersInfo
- Publication number
- ZA201409006B ZA201409006B ZA2014/09006A ZA201409006A ZA201409006B ZA 201409006 B ZA201409006 B ZA 201409006B ZA 2014/09006 A ZA2014/09006 A ZA 2014/09006A ZA 201409006 A ZA201409006 A ZA 201409006A ZA 201409006 B ZA201409006 B ZA 201409006B
- Authority
- ZA
- South Africa
- Prior art keywords
- diabetes biomarkers
- biomarkers
- diabetes
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Rehabilitation Therapy (AREA)
- Virology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Ecology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261651144P | 2012-05-24 | 2012-05-24 | |
| PCT/US2013/042627 WO2013177505A1 (en) | 2012-05-24 | 2013-05-24 | Diabetes biomarkers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201409006B true ZA201409006B (en) | 2016-07-27 |
Family
ID=49621783
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2014/09006A ZA201409006B (en) | 2012-05-24 | 2014-12-08 | Diabetes biomarkers |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US20130316375A1 (enExample) |
| EP (2) | EP2856149B1 (enExample) |
| JP (5) | JP6312332B2 (enExample) |
| KR (1) | KR102172285B1 (enExample) |
| CN (1) | CN104520707B (enExample) |
| AU (4) | AU2013266145A1 (enExample) |
| CA (1) | CA2874507A1 (enExample) |
| DK (1) | DK2856149T3 (enExample) |
| ES (1) | ES2810227T3 (enExample) |
| IN (1) | IN2014DN10259A (enExample) |
| MX (1) | MX357169B (enExample) |
| WO (1) | WO2013177505A1 (enExample) |
| ZA (1) | ZA201409006B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8735359B2 (en) | 2012-05-24 | 2014-05-27 | Orban Biotech Llc | Combinations of modalities for the treatment of diabetes |
| US20130316375A1 (en) * | 2012-05-24 | 2013-11-28 | Orban Biotech Llc | Diabetes biomarkers |
| AU2013284460A1 (en) | 2012-06-27 | 2015-01-29 | Dmnomore | CTLA4 fusion proteins for the treatment of diabetes |
| GB2523399B (en) | 2014-02-25 | 2019-03-13 | Orban Tihamer | A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence |
| CN107003315B (zh) * | 2014-12-25 | 2018-09-25 | 株式会社日立制作所 | 胰岛素分泌能力分析装置、具备该装置的胰岛素分泌能力分析系统以及胰岛素分泌能力分析方法 |
| CN105567851A (zh) * | 2016-02-29 | 2016-05-11 | 北京泱深生物信息技术有限公司 | 一种与糖尿病相关的分子标志物 |
| EP3433612B1 (en) * | 2016-03-22 | 2024-10-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and kits of assessing status, risk or prognosis of type 1 diabetes |
| JP7852926B2 (ja) | 2020-06-26 | 2026-04-28 | ファイム ファーマ リミテッド | 乾癬及び他の自己免疫疾患抗原免疫モジュレータ（ａｉｍ）治療プラットフォーム |
| WO2022264088A1 (en) | 2021-06-17 | 2022-12-22 | Phaim Pharma Ltd. | Individualized cell therapy using patient-derived antigen-specific regulatory t cells |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090246212A1 (en) * | 2005-09-30 | 2009-10-01 | Kyoto University | Development of method for screening for drug capable of improving production of regulatory t cells and method for producing regulatory t cells using immunosuppressive macrolide antibiotic |
| WO2009120341A2 (en) * | 2008-03-24 | 2009-10-01 | University Of South Florida | Biomarkers for predicting response to immunosuppressive therapy |
| US20100080784A1 (en) * | 2008-09-12 | 2010-04-01 | Torrey Pines Institute For Molecular Studies | Methods for treating cachexia and lymphopenia |
| US20130316375A1 (en) * | 2012-05-24 | 2013-11-28 | Orban Biotech Llc | Diabetes biomarkers |
| JP7618502B2 (ja) * | 2021-05-14 | 2025-01-21 | 東京計器株式会社 | 船舶用自動操舵装置 |
-
2013
- 2013-03-14 US US13/803,581 patent/US20130316375A1/en not_active Abandoned
- 2013-05-24 CN CN201380027247.6A patent/CN104520707B/zh not_active Expired - Fee Related
- 2013-05-24 EP EP13794110.0A patent/EP2856149B1/en active Active
- 2013-05-24 WO PCT/US2013/042627 patent/WO2013177505A1/en not_active Ceased
- 2013-05-24 EP EP20184212.7A patent/EP3767295A1/en active Pending
- 2013-05-24 AU AU2013266145A patent/AU2013266145A1/en not_active Abandoned
- 2013-05-24 ES ES13794110T patent/ES2810227T3/es active Active
- 2013-05-24 DK DK13794110.0T patent/DK2856149T3/da active
- 2013-05-24 MX MX2014014348A patent/MX357169B/es active IP Right Grant
- 2013-05-24 KR KR1020147036002A patent/KR102172285B1/ko active Active
- 2013-05-24 CA CA2874507A patent/CA2874507A1/en active Pending
- 2013-05-24 JP JP2015514216A patent/JP6312332B2/ja active Active
-
2014
- 2014-12-02 IN IN10259DEN2014 patent/IN2014DN10259A/en unknown
- 2014-12-08 ZA ZA2014/09006A patent/ZA201409006B/en unknown
-
2016
- 2016-06-17 US US15/185,831 patent/US20160299128A1/en not_active Abandoned
-
2018
- 2018-02-19 JP JP2018027381A patent/JP6761827B2/ja not_active Expired - Fee Related
- 2018-12-28 US US16/235,556 patent/US20190137483A1/en not_active Abandoned
-
2019
- 2019-02-07 AU AU2019200824A patent/AU2019200824B2/en not_active Ceased
-
2020
- 2020-09-07 JP JP2020150183A patent/JP2021001899A/ja active Pending
-
2021
- 2021-04-28 AU AU2021202609A patent/AU2021202609A1/en not_active Abandoned
-
2022
- 2022-11-02 JP JP2022175993A patent/JP2023011814A/ja active Pending
-
2023
- 2023-04-27 US US18/140,214 patent/US20230333094A1/en not_active Abandoned
- 2023-08-31 AU AU2023222980A patent/AU2023222980A1/en not_active Abandoned
-
2024
- 2024-07-25 JP JP2024120652A patent/JP2024150702A/ja active Pending
-
2025
- 2025-04-10 US US19/175,610 patent/US20250237643A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3767295A1 (en) | 2021-01-20 |
| JP6312332B2 (ja) | 2018-04-18 |
| JP2023011814A (ja) | 2023-01-24 |
| AU2013266145A1 (en) | 2015-01-15 |
| US20190137483A1 (en) | 2019-05-09 |
| AU2023222980A1 (en) | 2023-09-21 |
| DK2856149T3 (da) | 2020-08-17 |
| KR102172285B1 (ko) | 2020-11-02 |
| US20250237643A1 (en) | 2025-07-24 |
| JP2018116061A (ja) | 2018-07-26 |
| JP2021001899A (ja) | 2021-01-07 |
| CN104520707B (zh) | 2018-03-27 |
| AU2019200824A1 (en) | 2019-04-04 |
| US20230333094A1 (en) | 2023-10-19 |
| EP2856149A1 (en) | 2015-04-08 |
| AU2019200824B2 (en) | 2021-06-24 |
| CA2874507A1 (en) | 2013-11-28 |
| IN2014DN10259A (enExample) | 2015-08-07 |
| ES2810227T3 (es) | 2021-03-08 |
| JP2024150702A (ja) | 2024-10-23 |
| US20160299128A1 (en) | 2016-10-13 |
| MX2014014348A (es) | 2015-06-05 |
| CN104520707A (zh) | 2015-04-15 |
| US20130316375A1 (en) | 2013-11-28 |
| AU2021202609A1 (en) | 2021-05-27 |
| JP2015520378A (ja) | 2015-07-16 |
| EP2856149A4 (en) | 2016-06-01 |
| JP6761827B2 (ja) | 2020-09-30 |
| EP2856149B1 (en) | 2020-07-08 |
| WO2013177505A1 (en) | 2013-11-28 |
| KR20150022878A (ko) | 2015-03-04 |
| MX357169B (es) | 2018-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB201213567D0 (en) | Biomarkers | |
| GB201201727D0 (en) | Indicating locations | |
| GB201211982D0 (en) | Biomarker | |
| GB2526439B (en) | Dual Configuartion computer | |
| GB201021502D0 (en) | Biomarkers | |
| GB201008340D0 (en) | Biomarkers | |
| GB201018056D0 (en) | Biomarkers | |
| DK2856149T3 (da) | Diabetesbiomarkører | |
| GB201104556D0 (en) | Biomarkers | |
| GB201210565D0 (en) | Biomarkers | |
| GB2504567B (en) | Anti-Relatch Mechanism | |
| GB201211158D0 (en) | Biomarkers and uses thereof | |
| GB201005561D0 (en) | Biomarkers | |
| GB201001444D0 (en) | Biomarkers | |
| PL2626134T3 (pl) | Pipeta | |
| GB201010316D0 (en) | Biomarkers | |
| EP2712550A4 (en) | LANCET | |
| GB201117172D0 (en) | Diabetes | |
| GB201113968D0 (en) | Prognostic methadology | |
| GB201005456D0 (en) | Biomarkers | |
| SG11201504853VA (en) | Immunoassay | |
| GB201209802D0 (en) | Biomarker | |
| GB201202944D0 (en) | Biomarker | |
| GB201210587D0 (en) | Predictive biomarker | |
| GB201001419D0 (en) | Biomarkers |